100mg SPN-812

DRUG3 trials

Sponsors

Supernus Pharmaceuticals, Inc.

Conditions

ADHDAttention-Deficit/Hyperactivity DisorderAttention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2

Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

CompletedNCT02633527

Supernus Pharmaceuticals, Inc.Attention-Deficit/Hyperactivity Disorder (ADHD)

Start: 2016-02-01End: 2016-07-25Updated: 2021-10-27

Phase 3

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD

CompletedNCT03247530

Supernus Pharmaceuticals, Inc.ADHD

Start: 2017-10-20End: 2018-09-12Updated: 2021-07-02

Phase 4

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

RecruitingNCT04781140

Supernus Pharmaceuticals, Inc.Attention-Deficit/Hyperactivity Disorder

Start: 2024-03-19End: 2028-01-01Target: 286Updated: 2026-09-11

Related Papers

Evaluation of the Efficacy of Viloxazine ER in Children and Adolescents with ADHD Inattentive and Combined Presentations

CNS Spectrums2024-10-01

Viloxazine Extended-Release Capsules in Children and Adolescents with ADHD: Final Results of a Long-Term, Phase 3, Open-Label Extension Study

CNS Spectrums2024-10-01

Extended-Release Viloxazine for the Treatment of Attention-Deficit Hyperactivity Disorder in School-Age Children and Adolescents.

2023-04-052 citations

Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials

Pediatric Drugs2021-09-1516 citations

Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder

International Journal of Clinical Practice2021-05-1010 citations

Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Journal of Child and Adolescent Psychopharmacology2021-02-1818 citations

A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children

Clinical Therapeutics2020-07-2581 citations